Market's view on polarean
Published on April 2024
- Concerns have been raised about the performance of Polarean’s sales force and their effectiveness in selling medical equipment, as there has been no significant movement in converting research hospitals to commercial terms over 15 months since FDA approval.
- Discussions suggest there may be a joint venture in the pipeline, which could provide the momentum needed for broader commercialisation of Polarean’s technologies.
- Doubts have been expressed about the actual market demand for Polarean’s patented technologies, despite the granting of patents.
- There is ongoing discourse regarding the financial strategies of Polarean, particularly around the avoidance of dilution and exploration of financing options slated for launch in Q2-2024.
- Positive sentiments exist around the potential of Polarean’s technology, especially with recent advancements and applications in non-invasive gas exchange visualisation and monitoring.
- Skepticism is noted towards overly optimistic projections about the company’s future without concrete evidence or official announcements (RNS).
- It was mentioned that if significant updates or confirmations regarding Polarean’s status or strategy were available, they would need to be formally announced through regulatory news services.